FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

-	-	-	_			•			_		_	_	-	
٧	as	h	in	at	or	١.	D	.C.	2	054	9			

, D.C. 20549	OMB APPROVA
	OND ALL INOVA

- 1	OWID 7 II THE	, ,, ,_								
	OMB Number:	3235-0287								
	Estimated average burden									
	houre per reenonee:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of n Lesley	Reporting Person* Ann			2. Issuer Name and Ticker or Trading Symbol Aligos Therapeutics, Inc. [ALGS]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title				
(Last) (First) (Middle) C/O ALIGOS THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 03/01/2024						Officer (give title below) See Remarks				becity
		IVE, 2ND FLO	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SOUTH SAN FRANCISCO CA 94080					X Form filed by One Reporting Person Form filed by More than One Reporting Person									ing		
(City)	(S	tate)	F	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,		Code (Instr.					Form	: Direct I Indirect E str. 4) (7. Nature of indirect Beneficial Ownership Instr. 4)	
					Code V Amount (A) or (D)		r Price	Transaction(s) (Instr. 3 and 4)								
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Descurity or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date if any (Month/Day/Yea	Date, Transaction Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code V (A) (D) Date Expiration Date Title					Amount or Number of Shares		(Instr. 4)							
Stock Option (Right to Buy)	\$1.13	03/01/2024		A		308,940		(1)	03/01/2034	Common Stock	308,940	\$0	308,94	10	D	

Explanation of Responses:

1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Chief Financial Officer

/s/ Lesley Ann Calhoun

03/04/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.